Scientists have uncovered a critical weakness in prostate cancer’s defences. The disease relies on two enzymes, PDIA1 and ...

New research reveals a drug developed by scientists at Oregon Health & Science University may develop into a new treatment ...

A protein involved with cell death can be manipulated to slow or reverse tumor growth, a pair of new studies in mice found.

A new molecule developed by researchers at Oregon Health & Science University offers a promising avenue to treat intractable ...

Tumors were eradicated in 30% of mice receiving cGAS LNPs injected into the tumor, in combination with immune checkpoint blockade.

Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy. When blocked, these enzymes cause the androgen receptor to collapse, ...

Cytochrome P450 enzymes constitute a highly diverse superfamily that is pivotal in the metabolism of endogenous and exogenous compounds. In the context of cancer research, members such as CYP1B1 and ...

Orbus Therapeutics, Inc., a private pharmaceutical company, today announced it will present updated results from the Phase 3 STELLAR trial investigating eflornithine at the Society for Neuro-Oncology ...

New clinical research has identified a blood test that can reveal which women are more likely to respond to a particular ...

A COMMON enzyme found in mammals that kills damaged cells before they become cancerous is being hailed as an important breakthrough in understanding the treatment of the disease. Researchers from the ...

Within each cell, there is a constant struggle between life-sustaining molecules and molecules that could hasten its demise.

Celcuity hopes to "solve a 20-year riddle" in cancer treatment. The journey has sent the biotech stock flying as much as 534% ...